DK1612203T3 - Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid - Google Patents
Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochloridInfo
- Publication number
- DK1612203T3 DK1612203T3 DK04015091T DK04015091T DK1612203T3 DK 1612203 T3 DK1612203 T3 DK 1612203T3 DK 04015091 T DK04015091 T DK 04015091T DK 04015091 T DK04015091 T DK 04015091T DK 1612203 T3 DK1612203 T3 DK 1612203T3
- Authority
- DK
- Denmark
- Prior art keywords
- methylpropyl
- dimethylamino
- ethyl
- crystalline forms
- phenol hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04015091A EP1612203B1 (en) | 2004-06-28 | 2004-06-28 | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1612203T3 true DK1612203T3 (da) | 2007-12-03 |
Family
ID=34925507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04015091T DK1612203T3 (da) | 2004-06-28 | 2004-06-28 | Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid |
DK05770026.2T DK1799633T3 (da) | 2004-06-28 | 2005-06-27 | Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05770026.2T DK1799633T3 (da) | 2004-06-28 | 2005-06-27 | Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger |
Country Status (27)
Country | Link |
---|---|
US (16) | US20070213405A1 (da) |
EP (2) | EP1612203B1 (da) |
JP (1) | JP4990764B2 (da) |
KR (1) | KR101096501B1 (da) |
CN (1) | CN1997621B (da) |
AR (2) | AR049949A1 (da) |
AT (2) | ATE368639T1 (da) |
AU (1) | AU2005256512B2 (da) |
BR (2) | BR122018014454B8 (da) |
CA (1) | CA2572147C (da) |
CY (2) | CY1106929T1 (da) |
DE (2) | DE602004007905T2 (da) |
DK (2) | DK1612203T3 (da) |
EC (1) | ECSP17046065A (da) |
ES (2) | ES2291780T3 (da) |
HR (1) | HRP20110050T8 (da) |
IL (1) | IL180373A (da) |
MX (1) | MXPA06014741A (da) |
NO (3) | NO338605B1 (da) |
NZ (1) | NZ551605A (da) |
PE (1) | PE20060372A1 (da) |
PL (2) | PL1612203T3 (da) |
PT (2) | PT1612203E (da) |
RU (1) | RU2423345C2 (da) |
SI (2) | SI1612203T1 (da) |
WO (1) | WO2006000441A2 (da) |
ZA (1) | ZA200700774B (da) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
SI1612203T1 (sl) * | 2004-06-28 | 2007-12-31 | Gruenenthal Chemie | Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
CN104447360B (zh) * | 2007-12-07 | 2017-04-12 | 格吕伦塔尔有限公司 | (1r,2r)‑3‑(3‑二甲基氨基‑1‑乙基‑2‑甲基‑丙基)‑苯酚的结晶变体 |
NZ586792A (en) | 2008-01-25 | 2012-09-28 | Gruenenthal Chemie | Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces |
KR101690094B1 (ko) | 2008-05-09 | 2016-12-27 | 그뤼넨탈 게엠베하 | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 |
US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
PL2456424T3 (pl) | 2009-07-22 | 2013-12-31 | Gruenenthal Gmbh | Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
EP2566461A2 (de) | 2010-05-05 | 2013-03-13 | Ratiopharm GmbH | Festes tapentadol in nicht-kristalliner form |
RS61515B1 (sr) * | 2010-07-23 | 2021-03-31 | Gruenenthal Gmbh | Soli ili kokristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola |
BR112013005194A2 (pt) | 2010-09-02 | 2016-05-03 | Gruenenthal Gmbh | forma de dosagem resistente à violação compreendendo sal inorgânico |
ES2487244T3 (es) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico |
WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
WO2012119728A1 (en) * | 2011-03-04 | 2012-09-13 | Grünenthal GmbH | Parenteral administration of tapentadol |
EA033171B1 (ru) | 2011-03-04 | 2019-09-30 | Грюненталь Гмбх | Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол |
HUE046557T2 (hu) | 2011-03-04 | 2020-03-30 | Gruenenthal Gmbh | Tapentadolt tartalmazó vizes gyógyszerészeti készítmény szájon át alkalmazásra |
KR20140053158A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
LT2736495T (lt) | 2011-07-29 | 2017-11-10 | Grünenthal GmbH | Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu |
WO2013111161A2 (en) * | 2012-01-10 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof |
WO2013120466A1 (en) | 2012-02-17 | 2013-08-22 | Zentiva, K.S. | A new solid form of tapentadol and a method of its preparation |
BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CZ304576B6 (cs) * | 2012-07-24 | 2014-07-16 | Zentiva, K.S. | Oxalát TAPENTADOLU a způsob jeho přípravy |
CN102924303B (zh) * | 2012-10-31 | 2013-11-20 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
US9599565B1 (en) * | 2013-10-02 | 2017-03-21 | Ondax, Inc. | Identification and analysis of materials and molecular structures |
WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
GB2523089A (en) * | 2014-02-12 | 2015-08-19 | Azad Pharmaceutical Ingredients Ag | Stable polymorph form B of tapentadol hydrochloride |
US20150320690A1 (en) | 2014-05-12 | 2015-11-12 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
JP6923447B2 (ja) | 2015-03-27 | 2021-08-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールの非経口投与のための安定な製剤 |
CA2983642A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3653599B1 (en) | 2016-04-19 | 2022-12-14 | ratiopharm GmbH | Crystalline tapentadol phosphate |
KR20190057349A (ko) | 2016-09-23 | 2019-05-28 | 그뤼넨탈 게엠베하 | 타펜타돌의 비경구 투여용 안정한 제제 |
WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
CA3196954A1 (en) | 2020-11-03 | 2022-05-12 | Josep Bassaganya-Riera | Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
EA003754B1 (ru) * | 1996-08-14 | 2003-08-28 | Джи. Ди. Сирл Энд Ко. | 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамид |
CN100338028C (zh) * | 2000-10-31 | 2007-09-19 | 山道士有限公司 | 盐酸文拉法辛的晶形 |
US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
US7208520B2 (en) * | 2001-09-13 | 2007-04-24 | Kissei Pharmaceutical Co., Ltd. | Crystals of hydroxynorephedrine derivative |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
SI1612203T1 (sl) * | 2004-06-28 | 2007-12-31 | Gruenenthal Chemie | Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida |
-
2004
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es not_active Expired - Lifetime
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 EP EP04015091A patent/EP1612203B1/en not_active Expired - Lifetime
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de not_active Expired - Lifetime
-
2005
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es active Active
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-27 CA CA2572147A patent/CA2572147C/en active Active
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en active Active
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de active Active
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja active Active
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 EP EP05770026A patent/EP1799633B1/en active Active
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en unknown
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko active Protection Beyond IP Right Term
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en active Application Filing
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
-
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
-
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
-
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
-
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en active Active
-
2011
- 2011-01-24 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
-
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
-
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
-
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
-
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
-
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
-
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
-
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es unknown
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
-
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
-
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
-
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1612203T3 (da) | Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid | |
DK3210965T3 (da) | Fremgangsmåde til fremstilling af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
DK2049464T3 (da) | Fremstilling af 3-[(1R,2R)-3-(dimethylamino)-1ethyl-2-methylpropyl]phenol | |
NO2017007I2 (no) | Eluxadoline eller en farmasøytisk akseptabel enantiomer, diastereomer, rasemat eller salt derav | |
ATE477257T1 (de) | Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen | |
DK1786403T3 (da) | Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
DK1817309T3 (da) | Acetamidforbindelser som fungicider | |
ITTO20040563A1 (it) | Calzature asimmetriche, particolarmente per il gioco del golf | |
NO20040218L (no) | Fremgangsmåte for ad hoc buffer | |
DK3173400T3 (da) | Medikamenter, der indeholder krystallinske modifikationer af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
ATE383768T1 (de) | Köderstationen | |
DE602005023972D1 (de) | Vereinfachte wafer-ausrichtung | |
NL1028193A1 (nl) | Farmaceutisch werkzame verbindingen. | |
NL1030382A1 (nl) | Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen. | |
DK1853576T3 (da) | Krystallinsk base af trans-1-((1R,3S)-6-chlor-3-phenylindan-1-yl)-3,3-dimethylpiperazin | |
DK1727782T3 (da) | Fremgangsmåde til fremstilling af aminophenolforbindelser | |
FI20045145A0 (fi) | Sijainninmääritysvastaanotin | |
AP2007003934A0 (en) | Hydrochloride of 4-ÄÄ4-ÄÄ4-(2-cyanoethenyl)-2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile | |
CY2004010I2 (el) | Phenyl carbamate | |
ES1058726Y (es) | Repartidor digital para telecomunicaciones. | |
ITPD20040243A1 (it) | Inserto per sottotacchi. | |
FI6536U1 (fi) | Istutuskuokka | |
ES1059186Y (es) | Caseta para sanitarios publicos. | |
ES1058525Y (es) | Cabezal para friegasuelos. | |
ATA80062005A (de) | Brille, insbesondere für den schiesssport |